<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346970</url>
  </required_header>
  <id_info>
    <org_study_id>2005-005694-30</org_study_id>
    <nct_id>NCT00346970</nct_id>
  </id_info>
  <brief_title>The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)</brief_title>
  <official_title>Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <brief_summary>
    <textblock>
      The aim of the present study is to characterize novel mechanisms whereby HDL may exert potent&#xD;
      vasculoprotective effects independent of reverse cholesterol transport, in particular the&#xD;
      effect of HDL on the regulation of the vascular NAD(P)H oxidase enzyme system, a major&#xD;
      vascular source of superoxide, known to be important for endothelial dysfunction. In&#xD;
      addition, the present study will characterize the effect of HDL on endothelial progenitor&#xD;
      cell (EPC) mobilization, nitric oxide production and in vivo regenerative capacity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antioxidative Properties of Endothelial Progenitor Cells</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FDD</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (HDL) Elevation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended-release Niacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-Release Niacin</intervention_name>
    <description>Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Statin treatment for at least 3 weeks&#xD;
&#xD;
          -  Reduced HDL: &lt; 40 mg/dL (1.03 mmol/L) in men or &lt; 50 mg/dL (1.29 mmol/L) in women&#xD;
&#xD;
          -  Plus TWO of the following (thereby defining the patients to have metabolic syndrome&#xD;
             (Grundy et al.; Circulation 2005)):&#xD;
&#xD;
          -  Elevated waist circumference: ≥ 102 cm (≥ 40 inches) in men or ≥ 88 cm (≥ 35 inches)&#xD;
             in women&#xD;
&#xD;
          -  Elevated triglycerides: ≥ 150 mg/dL (1.7 mmol/L&#xD;
&#xD;
          -  Elevated blood pressure: ≥ 130 mmHg systolic blood pressure or ≥ 80 mmHg diastolic&#xD;
             blood pressure or anti-hypertensive treatment&#xD;
&#xD;
          -  Elevated fasting glucose: ≥ 100 mg/dL or on drug treatment for elevated fasting&#xD;
             glucose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to niacin&#xD;
&#xD;
          -  Active liver disease or impaired liver function&#xD;
&#xD;
          -  Persistent elevation of transaminases&#xD;
&#xD;
          -  Cholestasis&#xD;
&#xD;
          -  Gastric ulcer&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  Gout&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Active infections&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Untreated concomitant diseases&#xD;
&#xD;
          -  Renal insufficiency or renal failure&#xD;
&#xD;
          -  Hypothyreosis&#xD;
&#xD;
          -  Alcoholism&#xD;
&#xD;
          -  Myopathies&#xD;
&#xD;
          -  Muscle pain under therapy with fibrates or statins&#xD;
&#xD;
          -  Hereditary muscle diseases in family history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut Drexler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf Landmesser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sajoscha A Sorrentino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>May 5, 2008</last_update_submitted>
  <last_update_submitted_qc>May 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2008</last_update_posted>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>High Density Lipoprotein</keyword>
  <keyword>Extended-Release Niacin</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Endothelial Progenitor Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

